NEW YORK (GenomeWeb News) – California's Medicaid program has begun covering XDx's molecular diagnostic test for heart transplant rejection, the Brisbane, Calif.-based firm announced today.

Medi-Cal has added XDx's test called AlloMap as a new, covered benefit for the monitoring of heart transplants for organ rejection. AlloMap is now covered by more than 200 insurers in the US, and more than 80 percent of tests performed during the past year have been reimbursed, XDx said.

About 2,100 heart transplants are performed each year in the US, XDx noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.